eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors
Editorial System
Submit your Manuscript
2/2021
vol. 7
 
Share:
Share:
abstract:

Inhibitory konwertazy a sartany w terapii schorzeń układu sercowo-naczyniowego

Bogusław Okopień
1

  1. Oddział Chorób Wewnętrznych i Farmakologii Klinicznej, Samodzielny Publiczny Centralny Szpital Kliniczny im. prof. Kornela Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach
Online publish date: 2021/05/22
View full text Get citation
 
The renin-angiotensin system (RAS) is an essential participant in the pathogenesis of several cardiovascular diseases. Currently, the most commonly used drugs affecting the RAS are angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB). Their mechanisms of action are similar but not identical. The choice of specific compound is often based on clinical context. In the article, differences in therapeutic effects have been shown. Afterwards, a summary of results of clinical trials and therapeutic recommendations of leading international scientific societies, including arterial hypertension, chronic heart failure, coronary artery disease, and type 2 diabetes mellitus, have been presented. Finally, statements published by international scientific societies regarding abrupt changes in the treatment of cardiovascular diseases during the COVID-19 pandemic have been provided.
keywords:

angiotensin converting enzyme inhibitors, angiotensin receptor blockers, arterial hypertension, chronic heart failure, coronary artery disease, type 2 diabetes mellitus

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.